← All trials
NCT05951725
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 11, 2023
- Primary completion
- Feb 1, 2024
- Completion date
- Aug 1, 2024
- First posted
- Jul 19, 2023
- Last posted
- Aug 16, 2023
- Enrollment
- 2520
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.